BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9858771)

  • 1. Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer.
    Vogt U; Bielawski K; Schlotter CM; Bosse U; Falkiewicz B; Podhajska AJ
    Gene; 1998 Nov; 223(1-2):375-80. PubMed ID: 9858771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical determination of the frequency of c-erbB-2 amplification in breast cancer.
    Hubbard AL; Doris CP; Thompson AM; Chetty U; Anderson TJ
    Br J Cancer; 1994 Sep; 70(3):434-9. PubMed ID: 7915911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
    Erdogan S; Ergin M; Tuncer I
    Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification.
    Dalifard I; Daver A; Goussard J; Lorimier G; Gosse-Brun S; Lortholary A; Larra F
    Int J Mol Med; 1998 May; 1(5):855-61. PubMed ID: 9852307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
    Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
    Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
    Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
    Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters.
    Odagiri E; Kanada N; Jibiki K; Demura R; Aikawa E; Demura H
    Cancer; 1994 Jun; 73(12):2978-84. PubMed ID: 7911069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene copy numbers of erbB oncogenes in human pheochromocytoma.
    Sworczak K; Zaczek A; Babinska A; Lisowska U; Bielawski KP; Falkiewicz B
    Oncol Rep; 2002; 9(6):1373-8. PubMed ID: 12375051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational research studies of erbB oncogenes: selection strategies for breast cancer treatment.
    Brandt BH; Beckmann A; Gebhardt F; Rötger A; Jackisch C; Assmann G; Zänker KS
    Cancer Lett; 1997 Oct; 118(2):143-51. PubMed ID: 9459204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
    Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
    Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
    Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
    J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M; Kodet R; Kalinová M; Hilská I
    Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix.
    Kihana T; Tsuda H; Teshima S; Nomoto K; Tsugane S; Sonoda T; Matsuura S; Hirohashi S
    Cancer; 1994 Jan; 73(1):148-53. PubMed ID: 7506116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction.
    Esteller M; García A; Martínez i Palones JM; Cabero A; Reventós J
    Cancer; 1995 Apr; 75(8):2139-46. PubMed ID: 7697605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor].
    Manavi M; Czerwenka KF; Zeillinger R; Speiser P; Kury F; Steinhart U; Peschke M; Kubista E; Reinold E
    Zentralbl Gynakol; 1992; 114(2):82-5. PubMed ID: 1350129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
    Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
    Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
    Colomer R; Lupu R; Bacus SS; Gelmann EP
    Br J Cancer; 1994 Nov; 70(5):819-25. PubMed ID: 7947086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of ERBB family mRNA expression in breast carcinomas.
    Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
    Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors.
    Nagai MA; Marques LA; Torloni H; Brentani MM
    Oncology; 1993; 50(6):412-7. PubMed ID: 7901824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.